Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the April 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the JNJ options chain for the new April 10th contracts and identified one put and one call contract of particular interest.
The put contract at the $230.00 strike price has a current bid of $2.01. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $230.00, but will also collect the premium, putting the cost basis of the shares at $227.99 (before broker commissions). To an investor already interested in purchasing shares of JNJ, that could represent an attractive alternative to paying $243.47/share today.
Because the $230.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 76%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.87% return on the cash commitment, or 7.43% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Johnson & Johnson, and highlighting in green where the $230.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $245.00 strike price has a current bid of $4.75. If an investor was to purchase shares of JNJ stock at the current price level of $243.47/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $245.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 2.58% if the stock gets called away at the April 10th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if JNJ shares really soar, which is why looking at the trailing twelve month trading history for Johnson & Johnson, as well as studying the business fundamentals becomes important. Below is a chart showing JNJ's trailing twelve month trading history, with the $245.00 strike highlighted in red:
Considering the fact that the $245.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 51%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.95% boost of extra return to the investor, or 16.58% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 25%, while the implied volatility in the call contract example is 22%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $243.47) to be 19%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Also see:
Earnings Surprises
WEYS Price Target
ATLO Dividend History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

April 10th Options Now Available For Johnson & Johnson (JNJ)

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $3.8 billion dollar outflow -- that's a 0.5% decrease week over week (from 1,020,782,116 to 1,015,232,116). Among the largest underlying components of SPY, in trading today Exxon Mobil Corp (Symbol: XOM) is off about 0.5%, Johnson & Johnson (Symbol: JNJ) is off about 0.8%, and Micron Technology Inc. (Symbol: MU) is higher by about 3.4%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performance of SPY, versus its 200 day moving average:
Looking at the chart above, SPY's low point in its 52 week range is $481.80 per share, with $697.84 as the 52 week high point — that compares with a last trade of $690.61. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Funds Holding JSCP
VHI Options Chain
Institutional Holders of SNAV
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Outflows: SPY, XOM, JNJ, MU

Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key drug Darzalex being considered the foundational gold standard treatment. Darzalex generated more than $14 billion in sales in 2025, rising 22% year over year and still going strong.
Its Oncology segment comprises around 27% of total revenues and 42% of its Innovative Medicine segment sales. Its oncology sales rose 20.9% on an operational basis in 2025, driven by strong market growth and share gains of key products such as Darzalex and prostate cancer drug, Erleada. The sales growth was partially dampened by lower sales of Imbruvica.
Three of J&J’s new cancer drugs are Carvykti, a BCMA CAR-T therapy for relapsed or refractory multiple myeloma, Tecvayli for relapsed or refractory multiple myeloma and Talvey, a novel bispecific therapy for heavily pretreated multiple myeloma. These drugs also contributed to top-line growth in 2026. Combined, they generated $3.0 billion in sales in 2025.
J&J expects the momentum to continue and targets its oncology sales to reach $50 billion by 2030. Though quite bullish, J&J seems quite confident that it can meet the target, citing strong growth in its marketed cancer drugs and new launches like Inlexzoh/TAR-200 in high-risk non-muscle invasive bladder cancer and the subcutaneous formulation of Rybrevant plus Lazcluze for advanced EGFR-mutated non-small cell lung cancer.
Inlexzoh, which was initially approved in the United States in September last year, is the first-of-its-kind drug-releasing system to provide sustained local delivery of a cancer treatment directly into the bladder. The subcutaneous formulation of Rybrevant plus Lazcluze was approved in the EU in April 2025 and in the United States in December 2025.
J&J believes its new cancer drugs, Talvey, Tecvayli and Rybrevant plus Lazcluze, have the potential to deliver peak sales of $5 billion.
Meanwhile, J&J’s oncology pipeline has gained strong momentum in the last couple of years with promising developments in colorectal and head and neck cancers. J&J is also building its oncology pipeline through M&A deals. Last year, it acquired Halda Therapeutics, which added a promising clinical-stage treatment for prostate cancer with potential across multiple tumor types.
Competition in the Oncology Space
Other large players in the oncology space are Pfizer PFE, AstraZeneca AZN, Merck MRK and Bristol-Myers.
Oncology sales comprise around 27% of Pfizer’s total revenues. Its oncology revenues grew 8% in 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev, which made up for declining sales of drugs like Ibrance. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics.
For AstraZeneca, oncology sales now comprise around 44% of total revenues. Sales in its oncology segment rose 14% at constant exchange rate (CER) in 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 50% of Merck’s pharmaceutical sales. Keytruda recorded sales of $31.7 billion in 2025, up 7% year over year.
Bristol-Myers’ key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 21% of its total revenues. Opdivo’s sales rose 8% to $10 billion in 2025.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry in the past year. The stock has risen 51% in the past year compared with a 12.7% appreciation of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 21.11 forward earnings, higher than 18.69 for the industry. The stock is also trading above its five-year mean of 15.65.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $11.49 to $11.54 over the past 60 days, while that for 2027 has gone up from $12.24 per share to $12.40 per share over the same timeframe.
Image Source: Zacks Investment Research
J&J has a Zacks Rank #3 (Hold) currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Can J&J Sustain Its Double-Digit Oncology Growth Streak?

Key Points
ACR Alpine Capital Research, LLC increased its stake in Arrow Electronics by 1,028,778 shares.
Quarter-end position value rose by approximately $87 million, reflecting both trading activity and stock price movement.
The trade represented approximately a 1.7% increase relative to the fund’s reported $6.4 billion in assets under management (AUM).
ACR Alpine Capital held a position valued at $379 million at the end of the fourth quarter.
The stake now represents 5.9% of reported AUM, placing it outside the fund’s top five holdings.
On Feb. 4, 2026, ACR Alpine Capital Research, LLC disclosed a significant buy of Arrow Electronics (NYSE:ARW) in the fourth quarter.
What happened
According to a filing with the Securities and Exchange Commission dated Feb. 4, 2026, ACR Alpine Capital Research, LLC acquired 1,028,778 additional shares of Arrow Electronics. The position’s quarter-end value increased by $87 million, reflecting the additional shares purchased and market pricing changes.
What else to know
The increase brings the Arrow Electronics position to 5.9% of ACR Alpine Capital Research, LLC’s 13F reportable AUM as of Dec. 31, 2025.
Top holdings after this filing:
NYSEMKT:GBIL: $811.0 million (12.6% of AUM)
NYSE:FDX: $502.8 million (7.8% of AUM)
NYSE:JNJ: $462.9 million (7.2% of AUM)
NYSE:THO: $424.4 million (6.6% of AUM)
NYSE:C: $418.8 million (6.5% of AUM)
As of Feb. 4, 2026, Arrow Electronics shares were trading at $137.99, up 21.3% over the past year and outperforming the S&P 500 by 7.27 percentage points.
Company overview
Revenue (TTM)
$30.8 billion
Net income (TTM)
$569.7 million
Market capitalization
$7.0 billion
Price (as of market close February 4, 2026)
$137.99
Company snapshot
Offers electronic components, enterprise computing solutions, and related services across the Americas, EMEA, and Asia Pacific regions; revenue is primarily driven by semiconductor, passive component, and computing solution distribution.
Operates a two-segment business model: Global Components focuses on component distribution and value-added services, while Global Enterprise Computing Solutions delivers datacenter, cloud, security, and analytics offerings, generating income through product sales and service integration.
Serves original equipment manufacturers, value-added resellers, managed service providers, contract manufacturers, and other commercial clients worldwide.
Arrow Electronics is a leading global technology distributor with a diversified revenue base and broad geographic reach. The company leverages its scale and logistics expertise to deliver a comprehensive suite of products and services to industrial and commercial customers. Strategic positioning in both component distribution and enterprise computing enables Arrow to address evolving technology needs and maintain a competitive advantage in the technology supply chain.
What this transaction means for investors
ACR Alpine Capital Research does extensive research on companies to identify potentially undervalued stocks. The fund added to several of its largest positions in the quarter, including FedEx, Johnson & Johnson, and Thor Industries. Arrow Electronics is outside its top five holdings, but made a significant purchase of over 1 million shares in the quarter.
Arrow Electronics distributes parts for cars, electronics, and data centers, among other things. The company experienced a recovery toward the end of the year. Its full-year revenue grew 10% to over $30 billion.
ACR Alpine Capital’s purchase appears to align with this sudden recovery in the business. Also, it suggests there could be more upside if business conditions in the industrial sector continue to improve.
On that note, the ISM Manufacturing PMI also rose above the crucial 50 level recently, signaling a broader recovery in the manufacturing sector. Arrow Electronics’ focus on shifting more investment to high-margin areas of its business puts it in a solid position to capitalize on this opportunity.
Should you buy stock in Arrow Electronics right now?
Before you buy stock in Arrow Electronics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arrow Electronics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,174,241!*
Now, it’s worth noting Stock Advisor’s total average return is 889% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 25, 2026.
Citigroup is an advertising partner of Motley Fool Money. John Ballard has no position in any of the stocks mentioned. The Motley Fool recommends FedEx and Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock

(RTTNews) - German pharmaceutical and life sciences major Bayer AG (BAYRY.PK, BAYZF.PK) announced that it has filed false advertising suit against Johnson & Johnson or J&J (JNJ) and Janssen Biotech, Inc. over the U.S. drug major's claims regarding NUBEQA for prostate cancer treatment.
Bayer alleges that J&J's claims regarding NUBEQA are deeply flawed and intentionally aimed at boosting sales of J&J's ERLEADA.
With the lawsuit filed in the United States District Court for the Southern District of New York, Bayer seeks preliminary and permanent injunctions in addition to damages.
The suit follows J&J's refusal to cease and desist its promotion of a scientifically flawed real-world evidence analysis, which conveys false information to patients and healthcare providers regarding the efficacy of NUBEQA.
The German firm noted that J&J's promotional efforts, which include a press release issued to media and two presentations made available on its Medical Connect website, are commercial speech aimed at promoting its branded product that violate the Lanham Act, a federal law.
The law prohibits a company from making false or misleading commercial representations about a product's safety, efficacy, or characteristics.
According to Bayer, superiority claims of ERLEADA are false and derived from an analysis with numerous and fatal methodological flaws. They are based on scientifically flawed data and are not supported by a true head-to-head clinical trial. With the flawed analysis, J&J aims to increase its market share in a concentrated and increasingly competitive prostate cancer treatment market, the company noted.
Bayer added that J&J's real-world data analysis has other issues, such as almost exclusively unapproved use of NUBEQA; short follow-up time of less than 24 months for the majority of patients; treatment arms varied greatly in size; inferior data sources as the basis for its review; and improper control for comorbidities.
In the overnight trading, J&J shares were losing around 0.74 percent, after closing Monday's regular trading 1.4 percent higher at $245.84.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bayer Sues J&J Over Prostate Cancer Treatment Promotion Dispute

Johnson & Johnson JNJ and AbbVie ABBV are leading drugmakers with strong franchises in immunology, oncology and neuroscience. Beyond these areas, J&J also markets therapies for cardiovascular and metabolic diseases, pulmonary hypertension and infectious diseases, and maintains a sizable medical devices business. AbbVie, meanwhile, expanded into the aesthetics business through its 2020 acquisition of Allergan, the maker of Botox.
J&J’s key growth drivers include blockbuster drugs like Stelara and Darzalex, while AbbVie relies on Humira and newer immunology assets Skyrizi and Rinvoq. However, both face patent headwinds — AbbVie from Humira biosimilars and J&J from Stelara’s loss of exclusivity (LOE) — making pipeline execution and business development critical for sustained growth.
The stock that looks more attractive now can be determined based on balance sheet strength, pipeline depth and the pace of post-patent recovery. Let’s break down.
The Case for J&J
J&J’s biggest strength is its diversified business model, as it operates through pharmaceuticals and medical devices divisions. It has more than 275 subsidiaries and boasts 28 platforms or products with more than $1 billion in annual sales. Its diversification helps it to withstand economic cycles more effectively. It also boasts strong cash flows and has consistently increased its dividends for 63 consecutive years.
J&J’s Innovative Medicine unit is showing a growth trend. The segment’s sales rose 4.1% on an organic basis in 2025 despite Stelara LOE and the negative impact of the Part D redesign. Growth was driven by J&J’s key drugs like Darzalex, Erleada and Tremfya. New drugs like Carvykti, Tecvayli, Talvey, Rybrevant and Spravato also contributed significantly to growth.
J&J’s MedTech business has improved in the past three quarters, driven by the acquired cardiovascular businesses, Abiomed and Shockwave, as well as Surgical Vision and wound closure in Surgery. Improvements in J&J’s electrophysiology business also drove growth. MedTech sales rose 4.3% on an organic basis in 2025.
J&J also rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones that will help drive growth through the back half of the decade. In 2025, it gained approval for new products like Inlexzoh/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for treating generalized myasthenia gravis. In 2025, J&J invested more than $32 billion in R&D and M&A, including the acquisitions of Intra-Cellular Therapies and Halda Therapeutics.
J&J believes 10 of its new products/pipeline candidates in the Innovative Medicine segment have the potential to deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta, Inlexzo, Rybrevant, plus Lazcluze and Icotyde.
However, J&J faces its share of headwinds like the legal battle surrounding its talc lawsuits, the Stelara patent cliff, the upcoming LOE of key drugs Opsumit and Simponi and softness in MedTech China.
The Case for AbbVie
AbbVie has successfully navigated the LOE of its blockbuster drug, Humira, which once generated more than 50% of its total revenues. It has accomplished this by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
Skyrizi and Rinvoq generated combined sales of $26.0 billion in 2025, exceeding expectations and representing year-over-year growth of more than 40%. In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion, which is $0.5 billion more than its 2027 long-term guidance of $31 billion.
AbbVie’s neuroscience portfolio is also contributing to top-line growth. Sales of its neuroscience drugs increased almost 20% to $10.8 billion in 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta.
Its oncology segment generated combined revenues of $6.6 billion in 2025, up 1.5% year over year as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, partially offset the decline in Imbruvica sales.
AbbVie has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline that should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, and also inking some early-stage deals in oncology and neuroscience areas. In 2025, AbbVie invested more than $5 billion to acquire innovative pipeline candidates.
However, the company faces some near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and declining sales of its Aesthetics unit due to continued macro challenges and weakened consumer sentiment. Global sales of the aesthetics portfolio declined 0.6% in 2024 and 5.9% in 2025.
How Do Estimates Compare for JNJ & ABBV?
The Zacks Consensus Estimate for J&J’s 2026 sales and EPS imply a year-over-year increase of 6.5% and 7.0%, respectively. The Zacks Consensus Estimate for 2026 earnings has risen from $11.51 to $11.54 over the past 30 days, while that for 2027 has gone up from $12.25 per share to $12.40 per share over the same timeframe.
JNJ Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for AbbVie’s 2026 sales and EPS implies a year-over-year increase of 9.4% and 8.74%, respectively. The Zacks Consensus Estimate for 2026 earnings has risen from $14.37 to $14.49 per share over the past 30 days, while that for 2027 has declined from $16.28 per share to $16.22 per share over the same timeframe.
ABBV Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of J&J & ABBV
Stocks of both JNJ and ABBV have risen in the past year. While J&J’s stock has risen 48.1%, AbbVie’s stock has risen 10.2% compared with the industry’s increase of 12.1%
Image Source: Zacks Investment Research
AbbVie looks more attractive than JNJ from a valuation standpoint. Going by the price/earnings ratio, AbbVie’s shares currently trade at 15.25 forward earnings, lower than 18.46 for the industry, but higher than its 5-year mean of 13.69. J&J’s shares currently trade at 20.79 forward earnings, which is higher than the industry as well as the stock’s 5-year mean of 15.65.
Image Source: Zacks Investment Research
ABBV offers a slightly higher yield. J&J’s dividend yield is 2.1%, while AbbVie’s is around 3.1%.
Image Source: Zacks Investment Research
JNJ or ABBV: Which is a Better Pick?
AbbVie and J&J have a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie delivered robust net sales growth in 2025, which is just the second full year following the Humira LOE in the United States. Sales of AbbVie’s ex-Humira drugs rose more than 14% (on a reported basis) in the fourth quarter, which was above its expectations, driven by Skyrizi, Rinvoq and neuroscience.
It expects a high single-digit revenue growth through 2029, as the company has no significant LOE events for the rest of this decade. A substantial portion of this growth is expected to be driven by the robust performance of Skyrizi and Rinvoq. With no significant LOEs in this decade, AbbVie enjoys the flexibility to invest more in R&D to continue to acquire external innovation.
Similarly, J&J’s stock has shown steady revenue and EPS growth for years. J&J outperformed financial expectations in 2025 and looks optimistic for continued strong momentum in 2026 with a target to generate around $100 billion in revenues in the year. J&J expects sales growth in both segments to be higher in 2026.
As you can see, both companies have done well in 2025 and look optimistic for continued growth in 2026. J&J has a slight edge over AbbVie simply on the basis of a better stock performance and stronger estimate revisions, which reflect analysts’ optimistic outlook for future growth. AbbVie’s stock has been suppressed post fourth-quarter results despite beating estimates. This has been due to a decline in sales of its oncology drugs in the fourth quarter, weakness in the aesthetics segment and overall market caution about growth sustainability.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
See Our Newest 5 Stocks Set to Double Picks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs

(RTTNews) - Blackstone Life Sciences, a division of Blackstone Inc. (BX), Monday announced a research and development funding agreement with Johnson & Johnson (JNJ) to advance the clinical development of bleximenib for the treatment of acute myeloid leukemia.
Under this agreement, bleximenib's promising clinical data along with Johnson & Johnson's deep expertise in hematologic malignancies is expected to create a strong foundation to address critical gaps in patient care.
Meanwhile, Johnson & Johnson and funds managed by the company will jointly finance a portion of the ongoing and future clinical trials of bleximenib.
In the pre-market hours, BX is trading at $120.25, down 0.85 percent, and JNJ is trading at $242.52 on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Blackstone Life Sciences Signs Deal With JNJ To Jointly Fund Clinical Development Of Bleximenib

Key Points
Johnson & Johnson is a core player in global healthcare.
A diverse portfolio, fortress-like balance sheet, and industry tailwinds cement a growing dividend.
The company's growth could accelerate, adding a dash of upside for long-term investors.
Whether you plan on retiring a millionaire or already are one, your investing strategy is likely shifting over time. You spend your working years looking for upside in the name of growing your nest egg as much as possible. But as you age, stability and consistency become more important.
Dividend-paying companies can be a great way to add balance to your portfolio. They pay shareholders a portion of their profits, allowing investors to enjoy gains without having to sell their shares. The best companies can continue to grow while paying you more. That really is the best of both worlds.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Johnson & Johnson (NYSE: JNJ) is a legend among dividend investors. It's a Dividend King, meaning it has paid and raised its dividend for at least 50 consecutive years. Here's why it can still be an excellent anchor for a millionaire's portfolio -- or anyone's, for that matter.
A central figure in an evergreen industry
It's not easy to grow for decades on end, but Johnson & Johnson sits in a rare seat as a leader in a multitrillion-dollar global healthcare industry that continues to grow year after year. In the United States alone, total healthcare spending surpassed $5.3 trillion in 2024 and continues to grow at a pace in the mid- to high single digits.
J&J develops and sells pharmaceutical drugs and medical devices for a wide range of disciplines, from oncology to immunology and cardiovascular to orthopedics. The products accounting for over 75% of Johnson & Johnson's sales hold top-two market share positions in their respective applications, giving you an idea of just how strong the brand is across the board.
The financial firepower to help you sleep well at night
Deep pockets are a competitive advantage in the healthcare business. J&J's size and excellent financials allow it to invest in developing new products, acquire emerging competitors, and raise its dividend simultaneously.
The stock currently yields a solid 2.1%, and management has raised the dividend for 63 consecutive years. The dividend is also about as safe as they come; it costs less than half of this year's earnings estimates. And Johnson & Johnson is one of only two companies with the highest available credit rating (AAA), which all but guarantees access to debt in a pinch.
Remember that J&J is one of the world's largest companies, with a market cap approaching $590 billion today. It's probably not going to make anyone rich overnight. That said, there's still upside in the stock; management believes the business could accelerate to double-digit growth by the end of this decade.
Johnson & Johnson's mix of safety and growth potential makes it a fine choice to anchor a portfolio, protecting the wealth you've worked hard to accumulate.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 22, 2026.
Justin Pope has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio

Key Points
Johnson & Johnson is a Dividend King.
Its size and breadth have allowed it to flourish despite the many changes in the healthcare space over the years.
Its total return over the past decade tops 200%.
It's easy to get caught up in the latest hot stock, the newest trend, the flashiest sector. However, if you want steady, dependable income and a strong total return, buy Johnson & Johnson (NYSE: JNJ).
Yes, I know that's a boring statement, but if you want the closest thing to a guarantee other than death and taxes, the healthcare giant is the way to go. That's why I bought J&J shares years ago, and I don't ever plan on selling them.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Why do I love Johnson & Johnson's stock? Let me count the ways.
Reason No. 1: It has raised its dividend for 63 consecutive years
Let that sink in for a moment. The company is a Dividend King, one of a small group of companies that have raised their payouts for 50 or more consecutive years. It began raising its dividend in 1963, when John F. Kennedy was president. And amid all the upheaval since -- wars, economic downturns, and major changes in healthcare -- it has steadily kept boosting it.
Over the past decade, it has consistently provided single-digit percentage dividend increases, but those added up to a 73% total increase over that period. Last year, it raised its quarterly payout by 4.8% to $1.30 per share. At the stock's current price, that gives it a yield of 2.1%, almost double the S&P 500's average yield in December of 1.15%.
Moreover, the company's payout ratio of 46.3% shows it has plenty of room to continue those increases. While it paid out $12.4 billion in dividends in 2025, it produced about $20 billion in free cash flow.
Reason No. 2: Its total return outpaced the S&P 500 over the past year
Johnson & Johnson shares delivered a total return of more than 60% over the past year, about five times the return of the S&P 500. That's pretty good for a "boring" stock, though in most years, its total returns have been far more pedestrian.
The company did a lot right this year. Revenue rose 6% to $94.2 billion, while earnings per share (EPS) grew by 90.5% to $11.03. Adjusted EPS was $10.79, up 8.1%. In 2026, management is guiding for revenue in the $100 billion to $101 billion range, which would be a rise of 6.7% at the midpoint. It projects operational EPS to be between $11.43 and $11.63, an increase of 6.9% at the midpoint.
Reason No. 3: It isn't stuck in the past
Yes, the company has a 140-year history, but it also has its eyes firmly fixed on the future. It just announced plans to spend $1 billion on a next-generation cell manufacturing facility outside Philadelphia.
The new plant will support Johnson & Johnson's objective of making the majority of its advanced medicines within the U.S., which will allow it to meet domestic demand while reducing its tariff costs. The company said it plans an overall outlay of $55 billion in U.S. manufacturing, research and development (R&D), and technology through early 2029.
J&J consistently spends big on R&D -- $14.6 billion in 2025 alone -- and that pays off. Last year, it had 28 programs with $1 billion or more in sales. It also had 51 therapies approved in its innovative medicine division, and 15 new product launches in its medtech division.
Attributes like those may not be exciting, but they're why Johnson & Johnson is a stock I'll happily stick with for the long haul.
Should you buy stock in Johnson & Johnson right now?
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 22, 2026.
James Halley has positions in Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson

(RTTNews) - Johnson & Johnson (JNJ) announced new long-term results from the QUASAR long-term extension (LTE) study, showing that TREMFYA (guselkumab) sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis (UC).
At Week 140, 80.8% of patients receiving TREMFYA were in clinical remission. Additionally, 78.6% achieved histo-endoscopic mucosal improvement (HEMI), while 53.6% reached endoscopic remission. Approximately 89% of eligible participants completed treatment through Week 140, and nearly all patients in clinical remission at this timepoint were corticosteroid-free for at least eight weeks.
Durability of response was also demonstrated. Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140. Importantly, efficacy was consistent regardless of prior biologic or JAK inhibitor treatment history, and no new safety concerns were identified during the study period.
TREMFYA received U.S. Food and Drug Administration and European Commission approval for both SC and IV induction options for the treatment of adults with moderately to severely active Crohn's disease and U.S. FDA approval for both SC and IV induction options for the treatment of adults with moderately to severely active ulcerative colitis. TREMFYA® is approved by the EC for the treatment of adult patients with moderately to severely active ulcerative colitis and is currently administered via an IV induction regimen, followed by a SC maintenance regimen.
Johnson & Johnson closed on February 20 at $242.49, reflecting a decline of $4.42 or 1.79%. In after-hours trading, the stock inched up slightly to $242.51, a modest increase of $0.02 or 0.01%.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.